ID   ACTP2_ACTEQ             Reviewed;         214 AA.
AC   P61914; P17723; Q16993; Q9TWV2; Q9TWV3;
DT   07-JUN-2004, integrated into UniProtKB/Swiss-Prot.
DT   07-JUN-2004, sequence version 1.
DT   07-APR-2021, entry version 93.
DE   RecName: Full=DELTA-actitoxin-Aeq1a {ECO:0000303|PubMed:22683676};
DE            Short=DELTA-AITX-Aeq1a {ECO:0000303|PubMed:22683676};
DE   AltName: Full=Equinatoxin II {ECO:0000303|PubMed:8645323};
DE            Short=EqT II {ECO:0000303|PubMed:7912550};
DE            Short=EqTII {ECO:0000303|PubMed:8645323};
DE   AltName: Full=Equinatoxin-2 {ECO:0000305};
DE   Flags: Precursor;
OS   Actinia equina (Beadlet anemone).
OC   Eukaryota; Metazoa; Cnidaria; Anthozoa; Hexacorallia; Actiniaria;
OC   Actiniidae; Actinia.
OX   NCBI_TaxID=6106;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=8645323; DOI=10.1006/bbrc.1996.0391;
RA   Anderluh G., Pungercar J., Strukelj B., Macek P., Gubensek F.;
RT   "Cloning, sequencing, and expression of equinatoxin II.";
RL   Biochem. Biophys. Res. Commun. 220:437-442(1996).
RN   [2]
RP   PROTEIN SEQUENCE OF 36-214, AND CIRCULAR DICHROISM ANALYSIS.
RX   PubMed=7912550; DOI=10.1016/0005-2736(94)90119-8;
RA   Belmonte G., Menestrina G., Pederzolli C., Krizaj I., Gubensek F., Turk T.,
RA   Macek P.;
RT   "Primary and secondary structure of a pore-forming toxin from the sea
RT   anemone, Actinia equina L., and its association with lipid vesicles.";
RL   Biochim. Biophys. Acta 1192:197-204(1994).
RN   [3]
RP   PROTEIN SEQUENCE OF 36-80; 168-197 AND 200-214.
RA   Ferlan I., Jackson K.W.;
RT   "Partial amino acid sequence of equinatoxin.";
RL   Toxicon 21 Suppl. 3:141-144(1983).
RN   [4]
RP   PROTEIN SEQUENCE OF 105-118 AND 168-183.
RX   PubMed=1361161; DOI=10.1248/cpb.40.2873;
RA   Komatsu S., Furukawa K., Abe K., Hirano H., Ueda M.;
RT   "Isolation and characterization of equinatoxins from the sea anemone
RT   Actinia equina L.";
RL   Chem. Pharm. Bull. 40:2873-2875(1992).
RN   [5]
RP   AMINO-ACID COMPOSITION, AND TOXIC DOSE.
RX   PubMed=2903587; DOI=10.1016/0041-0101(88)90183-3;
RA   Macek P., Lebez D.;
RT   "Isolation and characterization of three lethal and hemolytic toxins from
RT   the sea anemone Actinia equina L.";
RL   Toxicon 26:441-451(1988).
RN   [6]
RP   SPHINGOMYELIN-BINDING.
RX   PubMed=7679444; DOI=10.1007/bf02258530;
RA   Belmonte G., Pederzolli C., Macek P., Menestrina G.;
RT   "Pore formation by the sea anemone cytolysin equinatoxin II in red blood
RT   cells and model lipid membranes.";
RL   J. Membr. Biol. 131:11-22(1993).
RN   [7]
RP   MUTAGENESIS, SITE ARG-179 AND SER-195, AND DOMAINS N-TERMINAL AND TRP-RICH.
RX   PubMed=10429196; DOI=10.1046/j.1432-1327.1999.00477.x;
RA   Anderluh G., Barlic A., Podlesek Z., Macek P., Pungercar J., Gubensek F.,
RA   Zecchini M.L., Serra M.D., Menestrina G.;
RT   "Cysteine-scanning mutagenesis of an eukaryotic pore-forming toxin from sea
RT   anemone: topology in lipid membranes.";
RL   Eur. J. Biochem. 263:128-136(1999).
RN   [8]
RP   MUTAGENESIS OF TRP-80; 151-TRP-TRP-152 AND TRP-184, AND SITE INVOLVED IN
RP   THE INITIAL CONTACT WITH THE MEMBRANE.
RX   PubMed=10657261; DOI=10.1042/bj3460223;
RA   Malovrh P., Barlic A., Podlesek Z., Macek P., Menestrina G., Anderluh G.;
RT   "Structure-function studies of tryptophan mutants of equinatoxin II, a sea
RT   anemone pore-forming protein.";
RL   Biochem. J. 346:223-232(2000).
RN   [9]
RP   TWO STEPS FOR PORE FORMATION, AND SITE INVOLVED IN THE INITIAL CONTACT WITH
RP   THE MEMBRANE.
RX   PubMed=12198118; DOI=10.1074/jbc.m204625200;
RA   Hong Q., Gutierrez-Aguirre I., Barlic A., Malovrh P., Kristan K.,
RA   Podlesek Z., Macek P., Turk D., Gonzalez-Manas J.M., Lakey J.H.,
RA   Anderluh G.;
RT   "Two-step membrane binding by Equinatoxin II, a pore-forming toxin from the
RT   sea anemone, involves an exposed aromatic cluster and a flexible helix.";
RL   J. Biol. Chem. 277:41916-41924(2002).
RN   [10]
RP   TOPOLOGY OF N-TERMINAL REGION IN TWO STEPS OF PORE FORMATION.
RX   PubMed=12676945; DOI=10.1074/jbc.m300622200;
RA   Malovrh P., Viero G., Serra M.D., Podlesek Z., Lakey J.H., Macek P.,
RA   Menestrina G., Anderluh G.;
RT   "A novel mechanism of pore formation: membrane penetration by the N-
RT   terminal amphipathic region of equinatoxin.";
RL   J. Biol. Chem. 278:22678-22685(2003).
RN   [11]
RP   SPHINGOMYELIN-BINDING.
RX   PubMed=12668447; DOI=10.1016/s0006-3495(03)75044-9;
RA   Bonev B.B., Lam Y.H., Anderluh G., Watts A., Norton R.S., Separovic F.;
RT   "Effects of the eukaryotic pore-forming cytolysin Equinatoxin II on lipid
RT   membranes and the role of sphingomyelin.";
RL   Biophys. J. 84:2382-2392(2003).
RN   [12]
RP   SPHINGOMYELIN-BINDING, MUTAGENESIS OF TRP-147 AND TYR-148, SITES INVOLVED
RP   IN THE INITIAL BINDING TO THE LIPID MEMBRANE, AND HYDROPHOBIC INTERACTION.
RX   PubMed=18442982; DOI=10.1074/jbc.m708747200;
RA   Bakrac B., Gutierrez-Aguirre I., Podlesek Z., Sonnen A.F.-P.,
RA   Gilbert R.J.C., Macek P., Lakey J.H., Anderluh G.;
RT   "Molecular determinants of sphingomyelin specificity of a eukaryotic pore-
RT   forming toxin.";
RL   J. Biol. Chem. 283:18665-18677(2008).
RN   [13]
RP   REVIEW.
RX   PubMed=19268680; DOI=10.1016/j.toxicon.2009.02.026;
RA   Kristan K.C., Viero G., Dalla Serra M., Macek P., Anderluh G.;
RT   "Molecular mechanism of pore formation by actinoporins.";
RL   Toxicon 54:1125-1134(2009).
RN   [14]
RP   NOMENCLATURE.
RX   PubMed=22683676; DOI=10.1016/j.toxicon.2012.05.020;
RA   Oliveira J.S., Fuentes-Silva D., King G.F.;
RT   "Development of a rational nomenclature for naming peptide and protein
RT   toxins from sea anemones.";
RL   Toxicon 60:539-550(2012).
RN   [15]
RP   X-RAY CRYSTALLOGRAPHY (1.9 ANGSTROMS) OF 40-214.
RX   PubMed=11525171; DOI=10.1016/s0969-2126(01)00592-5;
RA   Athanasiadis A., Anderluh G., Macek P., Turk D.;
RT   "Crystal structure of the soluble form of equinatoxin II, a pore-forming
RT   toxin from the sea anemone Actinia equina.";
RL   Structure 9:341-346(2001).
RN   [16]
RP   STRUCTURE BY NMR OF 36-214.
RX   PubMed=11827489; DOI=10.1006/jmbi.2001.5321;
RA   Hinds M.G., Zhang W., Anderluh G., Hansen P.E., Norton R.S.;
RT   "Solution structure of the eukaryotic pore-forming cytolysin equinatoxin
RT   II: implications for pore formation.";
RL   J. Mol. Biol. 315:1219-1229(2002).
CC   -!- FUNCTION: Pore-forming protein that forms cations-selective hydrophilic
CC       pores of around 1 nm and causes cardiac stimulation and hemolysis. Pore
CC       formation is a multi-step process that involves specific recognition of
CC       membrane sphingomyelin (but neither cholesterol nor
CC       phosphatidylcholine) using aromatic rich region and adjacent
CC       phosphocholine (POC) binding site, firm binding to the membrane (mainly
CC       driven by hydrophobic interactions) accompanied by the transfer of the
CC       N-terminal region to the lipid-water interface and finally pore
CC       formation after oligomerization of monomers. Cytolytic effects include
CC       red blood cells hemolysis, platelet aggregation and lysis, cytotoxic
CC       and cytostatic effects on fibroblasts. Lethality in mammals has been
CC       ascribed to severe vasospasm of coronary vessels, cardiac arrhythmia,
CC       and inotropic effects.
CC   -!- SUBUNIT: Tetramer in the presence of a lipidic interface. Monomer, in
CC       soluble state.
CC   -!- SUBCELLULAR LOCATION: Secreted. Nematocyst. Target cell membrane.
CC       Note=Forms an alpha-helical membrane channel in the prey.
CC   -!- DOMAIN: The N-terminal region, before the pore is formed, is bound to
CC       the lipid membrane. It partitions into the lipid-water interface and
CC       stabilizes the monomeric molecule on the membrane. Finally, it
CC       traverses the bilayer, thus forming the transmembrane pore.
CC       {ECO:0000269|PubMed:10429196}.
CC   -!- TOXIC DOSE: LD(50) is 35 ug/kg by intravenous injection into mice.
CC       {ECO:0000269|PubMed:2903587}.
CC   -!- SIMILARITY: Belongs to the actinoporin family. Sea anemone subfamily.
CC       {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; U41661; AAC47005.1; -; mRNA.
DR   PIR; JC4682; JC4682.
DR   PDB; 1IAZ; X-ray; 1.90 A; A/B=36-214.
DR   PDB; 1KD6; NMR; -; A=36-214.
DR   PDB; 1TZQ; X-ray; 2.30 A; A=40-214.
DR   PDBsum; 1IAZ; -.
DR   PDBsum; 1KD6; -.
DR   PDBsum; 1TZQ; -.
DR   BMRB; P61914; -.
DR   SMR; P61914; -.
DR   EvolutionaryTrace; P61914; -.
DR   GO; GO:0005576; C:extracellular region; IEA:UniProtKB-SubCell.
DR   GO; GO:0042151; C:nematocyst; IEA:UniProtKB-SubCell.
DR   GO; GO:0044218; C:other organism cell membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0046930; C:pore complex; IEA:InterPro.
DR   GO; GO:0015267; F:channel activity; IEA:InterPro.
DR   GO; GO:0090729; F:toxin activity; IEA:UniProtKB-KW.
DR   GO; GO:0006812; P:cation transport; IEA:InterPro.
DR   GO; GO:0052331; P:hemolysis in other organism involved in symbiotic interaction; IEA:InterPro.
DR   GO; GO:0046931; P:pore complex assembly; IEA:InterPro.
DR   Gene3D; 2.60.270.20; -; 1.
DR   InterPro; IPR009104; Anemon_actinoporin-like.
DR   InterPro; IPR015926; Cytolysin/lectin.
DR   Pfam; PF06369; Anemone_cytotox; 1.
DR   SUPFAM; SSF63724; SSF63724; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Cleavage on pair of basic residues; Cytolysis;
KW   Direct protein sequencing; Hemolysis; Ion transport; Membrane; Nematocyst;
KW   Secreted; Signal; Target cell membrane; Target membrane; Toxin;
KW   Transmembrane; Transport.
FT   SIGNAL          1..19
FT                   /evidence="ECO:0000255"
FT   PROPEP          20..35
FT                   /evidence="ECO:0000269|PubMed:7912550, ECO:0000269|Ref.3"
FT                   /id="PRO_0000034830"
FT   CHAIN           36..214
FT                   /note="DELTA-actitoxin-Aeq1a"
FT                   /evidence="ECO:0000269|PubMed:7912550"
FT                   /id="PRO_0000034831"
FT   REGION          38..47
FT                   /note="Plays an important role in the hemolytic activity"
FT                   /evidence="ECO:0000250"
FT   REGION          46..65
FT                   /note="N-terminal region"
FT   REGION          140..155
FT                   /note="Trp-rich region, which is important for the binding
FT                   to lipid membrane"
FT                   /evidence="ECO:0000269|PubMed:10429196"
FT   MOTIF           179..181
FT                   /note="Cell attachment site"
FT                   /evidence="ECO:0000255"
FT   BINDING         89
FT                   /note="Phosphocholine"
FT                   /evidence="ECO:0000250"
FT   BINDING         122
FT                   /note="Phosphocholine"
FT                   /evidence="ECO:0000250"
FT   BINDING         140
FT                   /note="Phosphocholine"
FT                   /evidence="ECO:0000250"
FT   BINDING         142
FT                   /note="Phosphocholine"
FT                   /evidence="ECO:0000250"
FT   BINDING         168
FT                   /note="Phosphocholine"
FT                   /evidence="ECO:0000250"
FT   BINDING         172
FT                   /note="Phosphocholine"
FT                   /evidence="ECO:0000250"
FT   BINDING         173
FT                   /note="Phosphocholine"
FT                   /evidence="ECO:0000250"
FT   SITE            147
FT                   /note="Important in the initial contact with the lipid
FT                   membrane"
FT   SITE            148
FT                   /note="Important in the initial contact with the lipid
FT                   membrane"
FT   SITE            179
FT                   /note="Interacts with the lipid membrane"
FT   SITE            195
FT                   /note="Interacts with the lipid membrane"
FT   VARIANT         116
FT                   /note="P -> D"
FT   MUTAGEN         80
FT                   /note="W->F: Expressed only 7% of the wild-type hemolytic
FT                   activity."
FT                   /evidence="ECO:0000269|PubMed:10657261"
FT   MUTAGEN         147
FT                   /note="W->A: Inhibition of direct binding of
FT                   sphingomyelin."
FT                   /evidence="ECO:0000269|PubMed:18442982"
FT   MUTAGEN         148
FT                   /note="Y->A: Inhibition of direct binding of
FT                   sphingomyelin."
FT                   /evidence="ECO:0000269|PubMed:18442982"
FT   MUTAGEN         151..152
FT                   /note="WW->FF: Expressed only 31% of the wild-type
FT                   hemolytic activity."
FT                   /evidence="ECO:0000269|PubMed:10657261"
FT   MUTAGEN         184
FT                   /note="W->F: Expressed only 2% of the wild-type hemolytic
FT                   activity."
FT                   /evidence="ECO:0000269|PubMed:10657261"
FT   STRAND          43..45
FT                   /evidence="ECO:0007744|PDB:1IAZ"
FT   HELIX           46..48
FT                   /evidence="ECO:0007744|PDB:1IAZ"
FT   HELIX           51..60
FT                   /evidence="ECO:0007744|PDB:1IAZ"
FT   STRAND          65..78
FT                   /evidence="ECO:0007744|PDB:1IAZ"
FT   STRAND          80..89
FT                   /evidence="ECO:0007744|PDB:1IAZ"
FT   STRAND          98..100
FT                   /evidence="ECO:0007744|PDB:1IAZ"
FT   STRAND          104..111
FT                   /evidence="ECO:0007744|PDB:1IAZ"
FT   STRAND          114..116
FT                   /evidence="ECO:0007744|PDB:1IAZ"
FT   STRAND          121..129
FT                   /evidence="ECO:0007744|PDB:1IAZ"
FT   STRAND          134..141
FT                   /evidence="ECO:0007744|PDB:1IAZ"
FT   TURN            145..147
FT                   /evidence="ECO:0007744|PDB:1IAZ"
FT   STRAND          151..159
FT                   /evidence="ECO:0007744|PDB:1IAZ"
FT   HELIX           165..173
FT                   /evidence="ECO:0007744|PDB:1IAZ"
FT   STRAND          181..190
FT                   /evidence="ECO:0007744|PDB:1IAZ"
FT   STRAND          193..199
FT                   /evidence="ECO:0007744|PDB:1IAZ"
FT   STRAND          201..213
FT                   /evidence="ECO:0007744|PDB:1IAZ"
SQ   SEQUENCE   214 AA;  23796 MW;  182AD60801E41DF4 CRC64;
     MSRLIIVFIV VTMICSATAL PSKKIIDEDE EDEKRSADVA GAVIDGASLS FDILKTVLEA
     LGNVKRKIAV GVDNESGKTW TALNTYFRSG TSDIVLPHKV PHGKALLYNG QKDRGPVATG
     AVGVLAYLMS DGNTLAVLFS VPYDYNWYSN WWNVRIYKGK RRADQRMYEE LYYNLSPFRG
     DNGWHTRNLG YGLKSRGFMN SSGHAILEIH VSKA
//
